Back to top
Read MoreHide Full Article

Leading player in the field of women's health, Hologic, Inc. (HOLX - Free Report)  declared that the company’s subsidiary Cynosure has received FDA’s expanded clearance for SculpSure. This is Cynosure's clinically proven and non-invasive body contouring product to treat problems like fat on the back as well as inner and outer thighs. The SculpSure treatment had earlier achieved FDA approval for the treatment of abdomen and love handles (flanks).

SculpSure eliminates fat cells from problem areas without surgery, through a selective wavelength laser. The laser treatment destroys fat by raising the temperature of these cells. Patients are likely to achieve a slimmer appearance with this customized treatment plan, which takes only 25 minutes.

Per management, the addition of three known body problem areas to SculpSure's advanced treatment is likely to drive demand.

According to Markets and Markets, the global medical aesthetics market is expected to reach a worth of $13.29 billion by 2021, at a CAGR of 10.8% from 2016 to 2021. Thus, the company clearly has bountiful opportunities in this niche market, both globally and internationally.

Also, a research report by RnR Market Research suggests that the global body contouring market is expected to reach a worth of $1.1 billion by 2022 at a CAGR of 7.9%. In fact, data shows that the number of men who underwent non-invasive body contouring treatments in the U.S. has increased from 14,598 in 2012 to 26,902 by 2015, reflecting an annual increase of 22.6%. The company is taking strategic measures to capture the untapped market in the U.S.

Recent Developments

Hologic is about to complete a series of clinical trials for an indication to use SculpSure for the submental area. The company expects to receive regulatory clearance for the same in the first half of fiscal 2018.

Zacks Rank and Key Picks

Hologic currently carries a Zacks Rank #3 (Hold). A few better-ranked medical stocks are Align Technology, Inc. (ALGN - Free Report) , Hill-Rom Holdings Inc. (HRC - Free Report) and Accelerate Diagnostics, Inc. (AXDX - Free Report) . Notably, Align Technology sports a Zacks Rank #1 (Strong Buy), while Hill-Rom Holdings and Accelerate Diagnostics carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Align Technology has an expected long-term adjusted earnings growth of almost 24.1%. The stock has roughly added 28.1% over the last three months.

Hill-Rom Holdings has a long-term expected earnings growth rate of 17.5%. The stock has a solid one-year return of around 55%.

Accelerate Diagnostics has an expected long-term adjusted earnings growth of 30%. The stock has gained roughly 19.5% over the last three months.

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana. Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>



More from Zacks Analyst Blog

You May Like